News

Varisolve solves varices in veins
Enlarge image

Clinical TrialsUK

Varisolve solves varices in veins

20.11.2012 - British BTG has reported positive results of pivotal Phase III trials. Its drug Varisolve improved the symptoms of varicose veins in 80% of the cases.

PEM (Polidocanol endovenous microfoam) works in varicose veins, veins that have become enlarged and tortuous. BTG International Ltd., London (UK) announced on 19 November that full data from the two US pivotal Phase III trials VANISH-1 and VANISH-2 support previous positive results on PEM. PEM causes fibrosis inside varicose veins, occluding the lumen of the vessel, and reducing the appearance of the varicosity. BTG sells the compound under the brand name Varisolve. VANISH-2 data, presented at the 26th Annual Congress of the American College of Phlebology in Hollywood, Florida (USA) show that 80% of patients treated with PEM 0.5% or 1.0% dose concentrations, reported an improvement of symptoms compared to 20% in the placebo arm. In addition, 85% of patients demonstrated elimination of saphenofemoral junction reflux and/or occlusion of the great saphenous vein (GSV) and all incompetent veins, compared with 2% in the placebo arm.

Patients varied from young (21) to old (73) and baseline GSV diameters from intermediate (3 mm) to wide (19 mm). Side effects were mostly mild or moderate. Out of 230 PEM-treated patients, 24 experienced thrombi. However, all were small and most (77%) were asymptomatic, and – most importantly – all resolved or stabilised in a median time of 29 days. Also, VANISH-1 results support the efficacy of the polyethylen glycol compound. Here PEM treatment led to an improvement of the appearance of varicose veins as assessed by scrutinising photos of them before and after ultrasound-guided delivery of PEM into the incompetent vein.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/varisolve-solves-varices-in-veins.html

EbolaEUFrance

30.09.2014 In the face of the Ebola outbreak sweeping the West African countries, the EMA has started to review investigational treatments for the deadly virus disease.

FinancingSwitzerlandGermanyNetherlandsFrance

26.09.2014 Biotechnology has made the news in the stock market this month, as a wave of companies announced plans to launch IPOs on European exchanges later this year.

ResearchGermany

25.09.2014 After being hit hard by the Andromeda trial data falsification scandal, German biotech Evotec is moving back into calmer waters with new MS research projects.

FinancingNetherlands

23.09.2014 Dutch Biotech VC firm Aglaia has launched a new US$65m fund targeted towards biotechnology startups working on groundbreaking technologies aimed at preventing and curing cancer.

BusinessGermany

19.09.2014 In order to concentrate on the life science business, German industry giant Bayer is splitting off its plastics subgroup as a separate company.

FinanceSwitzerland

18.09.2014 Swiss biopharma Cardiorentis has received a €45m investment from overseas investment firm Healthcare Royalty Partners in order to finance the registration for its heart drug.

PoliticsEU

15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.

BiosimilarsGermanyFrance

12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.

FinancingNetherlands

11.09.2014 Cystic fibrosis specialist Proqr Therapeutics has set the terms for its upcoming IPO at US-American stock exchange NASDAQ.

Clinical TrialsUKSweden

09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CO.DON3.13 EUR5.03%
  • 4SC1.06 EUR3.92%
  • SANTHERA88.65 CHF2.78%

FLOP

  • CYTOS0.19 CHF-9.52%
  • WILEX2.13 EUR-6.99%
  • FORMYCON8.03 EUR-5.42%

TOP

  • PAION3.18 EUR33.6%
  • CO.DON3.13 EUR27.8%
  • FORMYCON8.03 EUR14.2%

FLOP

  • CYTOS0.19 CHF-26.9%
  • ADDEX3.13 CHF-18.1%
  • EVOTEC3.06 EUR-16.8%

TOP

  • SANTHERA88.65 CHF2155.7%
  • PAION3.18 EUR224.5%
  • CO.DON3.13 EUR222.7%

FLOP

  • CYTOS0.19 CHF-95.2%
  • 4SC1.06 EUR-43.9%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 30.09.2014